Literature DB >> 19573289

Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.

Cristiano E Busso1, Juan Garcia-Velasco, Raúl Gomez, Claudio Alvarez, Carlos Simón, Antonio Pellicer.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovulation induction, which may seriously affect the patient's health, with 0.1-2.0% of the patients developing severe forms of the syndrome. OHSS signs and symptoms are direct consequences of fluid shift from capillaries to the third space due to increased vascular permeability. The mechanisms of OHSS pathophysiology remain unknown but evidence obtained in animal models prove that vascular endothelial growth factor (VEGF) is directly involved and the inhibition of the VEGF system could prevent OHSS from occurring. Dopamine agonists impede the phosphorylation of the VEGF receptor 2 and reduce the incidence and severity of OHSS with a safe clinical profile. As far as is known, this is the first pathophysiological approach for treatment and prevention of OHSS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573289     DOI: 10.1016/s1472-6483(10)60044-2

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  8 in total

Review 1.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

2.  Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients.

Authors:  Mary E Sabatini; Ann M Wolkovich; Eric A Macklin; Diane L Wright; Irene Souter; Thomas L Toth
Journal:  J Assist Reprod Genet       Date:  2010-11-24       Impact factor: 3.412

3.  The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Cristiano Busso; Manuel Fernández-Sánchez; Juan Antonio García-Velasco; José Landeras; Augustín Ballesteros; Elkin Muñoz; Sandra González; Carlos Simón; Joan-Carles Arce; Antonio Pellicer
Journal:  Hum Reprod       Date:  2010-02-06       Impact factor: 6.918

4.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

5.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

6.  Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis.

Authors:  Nalini Mahajan; Shalu Gupta; Shilpa Sharma; Kumkum Rani; Padmaja Naidu; Puneet R Arora
Journal:  J Hum Reprod Sci       Date:  2015 Oct-Dec

7.  Effect of Bushen Yutai Recipe on IVF Patients Subjected to Mild Ovarian Stimulation.

Authors:  Xiaomei Jiang; Hua Yan; Xiufang Zhong; Guoqing Tong; Wuwen Zhang
Journal:  Front Med (Lausanne)       Date:  2020-11-12

8.  GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.

Authors:  Usama M Fouda; Ahmed M Sayed; Hesham S Elshaer; Bahaa Eldin M Hammad; Mona M Shaban; Khaled A Elsetohy; Mohamed A Youssef
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.